Gouty Arthritis (Gout) Pipeline Review, H2 2015
Summary
Global Markets Directs, Gouty Arthritis (Gout) Pipeline Review, H2 2015, provides an overview of the Gouty Arthritis (Gout)s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout)
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Gouty Arthritis (Gout) pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout)
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Gouty Arthritis (Gout) Overview 10
Therapeutics Development 11
Pipeline Products for Gouty Arthritis (Gout) - Overview 11
Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis 12
Gouty Arthritis (Gout) - Therapeutics under Development by Companies 13
Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes 15
Gouty Arthritis (Gout) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Gouty Arthritis (Gout) - Products under Development by Companies 20
Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes 22
Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development 23
AstraZeneca Plc 23
Celtaxsys, Inc. 24
CymaBay Therapeutics, Inc. 25
Delenex Therapeutics AG 26
Immune Response BioPharma, Inc. 27
IOmet Pharma 28
JW Pharmaceutical Corporation 29
LG Life Science LTD. 30
Monosol Rx, LLC 31
Nimbus Therapeutics, LLC 32
Omni Bio Pharmaceutical Inc. 33
Opsona Therapeutics Limited 34
PLx Pharma Inc. 35
Polaris Pharmaceuticals, Inc. 36
Selecta Biosciences, Inc. 37
Takeda Pharmaceutical Company Limited 38
Teijin Limited 39
TWi Pharmaceuticals, Inc. 40
Wellstat Therapeutics Corporation 41
Gouty Arthritis (Gout) - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
acebilustat - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
arhalofenate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AXIBU-03 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
colchicine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
diacerein - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
DLX-2323 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
DLX-2681 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
FcAAT-2 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
FcAAT-3 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
febuxostat - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
febuxostat XR - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IR-888 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
LC-350189 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
lesinurad sodium - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Moniclonal Antibody to Inhibit S100A9 Protein for Neurodegenerative Diseases, Chronic Inflammation and Autoimmune Disorders - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ND-2110 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ND-2158 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ND-346 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pegadricase - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pegadricase - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PL-4100 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
RDEA-3170 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Recombinant Protein to Replace Alpha-1 Antitrypsin Cardiovascular, Metabolic Disorders, Immunology, Gastrointestinal Disease - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
RLBN-1001 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
RLBN-2020 Series - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
RLBN-3010 Series - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecule Inflammasome Modulator Programme - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Small Molecules to Inhibit GLUT9 for Gout - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
URC-102 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
uriSHELS - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
WT-2107 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
XEN-102 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
XEN-104 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Gouty Arthritis (Gout) - Recent Pipeline Updates 96
Gouty Arthritis (Gout) - Dormant Projects 106
Gouty Arthritis (Gout) - Discontinued Products 107
Gouty Arthritis (Gout) - Product Development Milestones 108
Featured News & Press Releases 108
Nov 09, 2015: AstraZeneca Presents Positive Update on Lesinurad Renal Data in Gout Patients 108
Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 108
Oct 23, 2015: FDA Advisory Committee recommends the approval of lesinurad for gout patients 109
Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery 110
Aug 06, 2015: CymaBay Strengthens the Intellectual Property of Arhalofenate With Issuance of Two New Patents 111
Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe 111
Jun 13, 2015: AstraZeneca Announces Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at European League Against Rheumatism Annual Congress 112
Jun 12, 2015: CymaBay Therapeutics Presents Poster at EULAR 2015 113
Jun 10, 2015: Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout 114
Mar 23, 2015: CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City 115
Appendix 116
Methodology 116
Coverage 116
Secondary Research 116
Primary Research 116
Expert Panel Validation 116
Contact Us 116
Disclaimer 117
List Of Tables
Number of Products under Development for Gouty Arthritis (Gout), H2 2015 11
Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Comparative Analysis by Unknown Stage Development, H2 2015 19
Products under Development by Companies, H2 2015 20
Products under Development by Companies, H2 2015 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2015 22
Gouty Arthritis (Gout) - Pipeline by AstraZeneca Plc, H2 2015 23
Gouty Arthritis (Gout) - Pipeline by Celtaxsys, Inc., H2 2015 24
Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics, Inc., H2 2015 25
Gouty Arthritis (Gout) - Pipeline by Delenex Therapeutics AG, H2 2015 26
Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma, Inc., H2 2015 27
Gouty Arthritis (Gout) - Pipeline by IOmet Pharma, H2 2015 28
Gouty Arthritis (Gout) - Pipeline by JW Pharmaceutical Corporation, H2 2015 29
Gouty Arthritis (Gout) - Pipeline by LG Life Science LTD., H2 2015 30
Gouty Arthritis (Gout) - Pipeline by Monosol Rx, LLC, H2 2015 31
Gouty Arthritis (Gout) - Pipeline by Nimbus Therapeutics, LLC, H2 2015 32
Gouty Arthritis (Gout) - Pipeline by Omni Bio Pharmaceutical Inc., H2 2015 33
Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Limited, H2 2015 34
Gouty Arthritis (Gout) - Pipeline by PLx Pharma Inc., H2 2015 35
Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015 36
Gouty Arthritis (Gout) - Pipeline by Selecta Biosciences, Inc., H2 2015 37
Gouty Arthritis (Gout) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 38
Gouty Arthritis (Gout) - Pipeline by Teijin Limited, H2 2015 39
Gouty Arthritis (Gout) - Pipeline by TWi Pharmaceuticals, Inc., H2 2015 40
Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corporation, H2 2015 41
Assessment by Monotherapy Products, H2 2015 42
Number of Products by Stage and Target, H2 2015 44
Number of Products by Stage and Mechanism of Action, H2 2015 46
Number of Products by Stage and Route of Administration, H2 2015 48
Number of Products by Stage and Molecule Type, H2 2015 50
Gouty Arthritis (Gout) Therapeutics - Recent Pipeline Updates, H2 2015 96
Gouty Arthritis (Gout) - Dormant Projects, H2 2015 106
Gouty Arthritis (Gout) - Discontinued Products, H2 2015 107
List Of Figures
List of Figures
Number of Products under Development for Gouty Arthritis (Gout), H2 2015 11
Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Products, H2 2015 18
Assessment by Monotherapy Products, H2 2015 42
Number of Products by Top 10 Targets, H2 2015 43
Number of Products by Stage and Top 10 Targets, H2 2015 43
Number of Products by Top 10 Mechanism of Actions, H2 2015 45
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 45
Number of Products by Routes of Administration, H2 2015 47
Number of Products by Stage and Routes of Administration, H2 2015 47
Number of Products by Molecule Types, H2 2015 49
Number of Products by Stage and Molecule Types, H2 2015 49
